LifeMD, Inc. (NASDAQ:LFMDP) Short Interest Up 100.0% in March

LifeMD, Inc. (NASDAQ:LFMDP) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 400 shares, a growth of 100.0% from the February 28th total of 200 shares. Based on an average daily trading volume, of 2,700 shares, the days-to-cover ratio is presently 0.1 days.

LifeMD Stock Up 0.6 %

Shares of LFMDP stock traded up $0.14 during trading hours on Friday, hitting $24.89. The company’s stock had a trading volume of 1,538 shares, compared to its average volume of 2,747. LifeMD has a 12-month low of $20.25 and a 12-month high of $27.44. The company has a 50 day moving average of $22.86 and a 200 day moving average of $22.55.

LifeMD Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, April 4th will be issued a $0.5547 dividend. This represents a $2.22 annualized dividend and a yield of 8.91%. The ex-dividend date of this dividend is Friday, April 4th.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.